Role Definition
| Field | Value |
|---|---|
| Job Title | Clinical Data Analyst |
| Seniority Level | Mid-Level |
| Primary Function | Manages clinical trial data throughout the study lifecycle — performs data cleaning and query management, reviews CRFs for completeness, maps data to CDISC/SDTM standards, programs edit checks in EDC systems, reconciles safety data with pharmacovigilance databases, and supports regulatory submissions to the FDA/EMA. Works within pharma, biotech, or CRO environments under GCP guidelines. |
| What This Role Is NOT | Not a generic data analyst (requires clinical domain expertise, CDISC knowledge, GCP compliance). Not a biostatistician (doesn't design trials or run inferential statistics). Not a Clinical Data Manager (CDM is senior, owns the Data Management Plan end-to-end). Not a clinical research coordinator (CRC is site-based, manages patients). |
| Typical Experience | 3-5 years. Bachelor's in life sciences, public health, or health informatics. CDISC SDTM certification common. EDC platform experience (Medidata Rave, Veeva Vault CDMS, Oracle Clinical One). SAS or Python for data validation. |
Seniority note: Entry-level clinical data analysts doing basic data entry and query resolution would score deeper into Yellow or borderline Red. Senior Clinical Data Managers who own the DMP, lead cross-functional teams, and make judgment calls on data integrity for regulatory submissions would score higher Yellow or borderline Green.
Protective Principles + AI Growth Correlation
| Principle | Score (0-3) | Rationale |
|---|---|---|
| Embodied Physicality | 0 | Fully digital, desk-based. All work happens in EDC systems, SAS, and validation tools. |
| Deep Interpersonal Connection | 1 | Regular cross-functional coordination with CRAs, biostatisticians, and clinical scientists on query resolution and data readiness. Relationships matter but are transactional, not trust-based. |
| Goal-Setting & Moral Judgment | 1 | Follows established SOPs, protocols, and CDISC standards. Some interpretation required for ambiguous data quality issues, but operates within defined frameworks rather than setting direction. |
| Protective Total | 2/9 | |
| AI Growth Correlation | 0 | Neutral. Clinical trial volume grows steadily (~6-8% CAGR), sustaining baseline demand. AI doesn't directly create or eliminate this specific role — it transforms how the work is done. |
Quick screen result: Protective 2 + Correlation 0 — Likely Yellow Zone. Regulatory barriers may provide moderate protection above generic data analyst.
Task Decomposition (Agentic AI Scoring)
| Task | Time % | Score (1-5) | Weighted | Aug/Disp | Rationale |
|---|---|---|---|---|---|
| Clinical data cleaning & query management | 25% | 4 | 1.00 | DISPLACEMENT | AI agents can generate queries from edit check violations, flag discrepancies, and auto-resolve standard query types. Medidata Rave AI and Veeva Vault CDMS already automate query generation. Complex clinical judgment queries remain human-led, but these are the minority. |
| CRF design & database setup/testing | 15% | 3 | 0.45 | AUGMENTATION | AI assists with CRF template generation and UAT test case creation, but protocol-specific clinical knowledge and regulatory compliance review require human judgment. The analyst interprets protocol requirements and validates EDC configuration. |
| CDISC/SDTM mapping & compliance | 20% | 3 | 0.60 | AUGMENTATION | AI tools can suggest SDTM domain mappings from raw data, but regulatory validation requires human review. CDISC standards have nuances (supplemental qualifiers, custom domains) that need clinical context. FDA submission readiness demands human accountability. |
| Edit check programming & validation | 15% | 4 | 0.60 | DISPLACEMENT | Rule-based edit checks are highly automatable — AI generates validation rules from protocol specifications. AI agents can execute end-to-end from protocol text to programmed checks. Human validates output but doesn't need to be in the loop for each step. |
| Safety data review & SAE reconciliation | 10% | 2 | 0.20 | AUGMENTATION | Patient safety review carries regulatory liability. While AI flags discrepancies between clinical and safety databases, a human must verify SAE narratives, assess causality coding, and sign off. GCP mandates human accountability for safety data. |
| Regulatory documentation & submissions | 10% | 3 | 0.30 | AUGMENTATION | AI drafts data management sections of clinical study reports and generates submission-ready documentation. But regulatory submissions require human review for accuracy and completeness — FDA/EMA rejection consequences are significant. |
| Cross-functional coordination | 5% | 2 | 0.10 | AUGMENTATION | Coordinating with CRAs on site data quality, aligning with biostatisticians on analysis datasets, resolving protocol deviations. Human relationship and clinical context required. |
| Total | 100% | 3.25 |
Task Resistance Score: 6.00 - 3.25 = 2.75/5.0
Displacement/Augmentation split: 40% displacement, 60% augmentation, 0% not involved.
Reinstatement check (Acemoglu): Yes — AI creates new tasks for this role. Validating AI-generated queries and edit checks, auditing AI-driven SDTM mappings for regulatory compliance, configuring AI modules within EDC platforms, and ensuring AI tools meet 21 CFR Part 11 requirements. These reinstatement tasks partially offset displacement but don't fully compensate — the net effect is headcount compression with survivors doing higher-value work.
Evidence Score
| Dimension | Score (-2 to 2) | Evidence |
|---|---|---|
| Job Posting Trends | 0 | Clinical data management postings stable. Clinical trial volume growing 6-8% CAGR sustains baseline demand. Staffing shortages in clinical research persist (Merative 2026). But AI-driven platformization consolidating roles — fewer analysts needed per trial as automation matures. |
| Company Actions | 0 | No mass layoffs citing AI in clinical data management. CROs (Parexel, IQVIA, PPD) still hiring clinical data analysts. However, investment flowing to CDM platform automation (Veeva, Medidata) rather than headcount expansion. Function-spending growing faster than people-spending. |
| Wage Trends | 0 | Mid-level $75K-$105K, stable with modest growth tracking inflation. No significant premium for AI-adjacent skills yet within clinical data specifically. Healthcare sector wage growth positive but not exceptional. |
| AI Tool Maturity | -1 | Production tools performing 50-80% of core tasks with human oversight. Medidata Rave AI (automated query generation), Veeva Vault CDMS (AI-assisted data review), Oracle Clinical One (ML-driven edit checks). Anthropic observed exposure: Medical Records Specialists 66.7%, Health Information Technologists 30.6% — moderate-to-high for parent occupations. Tools are in production but regulatory validation requirements keep humans in the loop. |
| Expert Consensus | 0 | Mixed. Applied Clinical Trials (2026): "AI as default approach" in clinical data management. Merative (2026): automating manual testing and validation is key opportunity. But consensus is transformation, not elimination — regulatory requirements ensure human oversight persists. Role evolves from manual data work to AI oversight and regulatory compliance. |
| Total | -1 |
Barrier Assessment
Reframed question: What prevents AI execution even when programmatically possible?
| Barrier | Score (0-2) | Rationale |
|---|---|---|
| Regulatory/Licensing | 2 | Strong barrier. FDA 21 CFR Part 11 mandates validated systems with audit trails. GCP (ICH E6) requires documented human oversight of data management processes. CDISC compliance for regulatory submissions demands accountable humans. EU Clinical Trials Regulation (EU CTR) adds additional oversight requirements. Database locks require human sign-off. |
| Physical Presence | 0 | Fully remote/digital. All work performed in EDC systems and validation tools. |
| Union/Collective Bargaining | 0 | No union representation in pharma/biotech/CRO sector for this role. At-will employment. |
| Liability/Accountability | 1 | Moderate. Data integrity failures in clinical trials can delay or block drug approvals (multi-billion-dollar consequences for sponsors). FDA warning letters and consent decree risk. Individual accountability is organisational rather than personal criminal liability, but consequences are significant enough to mandate human oversight. |
| Cultural/Ethical | 1 | Moderate resistance. Clinical trial data directly affects patient safety decisions. Regulatory bodies, ethics committees, and pharma companies are conservative about removing human oversight from safety-relevant data processes. Trust in AI for safety data review is low — a wrong AI decision could affect patient lives. |
| Total | 4/10 |
AI Growth Correlation Check
Confirmed at 0 (Neutral). Clinical trial volume grows independently of AI adoption — driven by drug development pipelines, regulatory requirements, and disease burden. AI doesn't create more demand for clinical data analysts (unlike AI security engineers), nor does it directly eliminate the role (unlike self-service BI eliminating generic data analysts). AI transforms how the work is done — automating repetitive data cleaning while creating new AI oversight tasks. Net effect on headcount is mildly negative but not strongly correlated with AI adoption specifically.
JobZone Composite Score (AIJRI)
| Input | Value |
|---|---|
| Task Resistance Score | 2.75/5.0 |
| Evidence Modifier | 1.0 + (-1 × 0.04) = 0.96 |
| Barrier Modifier | 1.0 + (4 × 0.02) = 1.08 |
| Growth Modifier | 1.0 + (0 × 0.05) = 1.00 |
Raw: 2.75 × 0.96 × 1.08 × 1.00 = 2.8512
JobZone Score: (2.8512 - 0.54) / 7.93 × 100 = 29.1/100
Zone: YELLOW (Green >=48, Yellow 25-47, Red <25)
Sub-Label Determination
| Metric | Value |
|---|---|
| % of task time scoring 3+ | 85% |
| AI Growth Correlation | 0 |
| Sub-label | Yellow (Urgent) — AIJRI 25-47 AND >=40% of task time scores 3+ |
Assessor override: None — formula score accepted. The 29.1 accurately reflects a role that is materially protected by regulatory barriers compared to a generic data analyst (10.4) but still faces significant automation pressure on core tasks.
Assessor Commentary
Score vs Reality Check
The 29.1 sits 4 points above the Red Zone boundary, which is honest. The barrier modifier (1.08) is doing meaningful work — without regulatory barriers, this role would score approximately 25.1, right at the Red/Yellow boundary. The barriers are genuine and durable (FDA regulations don't relax quickly), but this is a barrier-dependent classification. If a future regulatory framework formally accepts AI-validated clinical data without human sign-off, this role drops to borderline Red. That scenario is unlikely within 5 years given FDA conservatism on patient safety data.
What the Numbers Don't Capture
- Function-spending vs people-spending. Investment in clinical data management platforms (Veeva, Medidata, Oracle) is growing 15-20% annually. But this spending goes to software, not headcount. Each platform upgrade reduces the number of analysts needed per trial. The market grows while human headcount stagnates or declines per trial.
- CRO consolidation compresses further. Large CROs (IQVIA, Covance, PPD/Thermo Fisher) are standardising CDM platforms across studies, creating economies of scale that reduce per-study analyst requirements. A mid-level analyst at a CRO faces more pressure than one at a pharma sponsor.
- CDISC domain knowledge creates a moat but not a wall. SDTM mapping expertise is genuinely specialised, but AI tools are learning CDISC standards rapidly. The moat protects for 3-5 years, not indefinitely.
Who Should Worry (and Who Shouldn't)
If you spend most of your day running edit checks, resolving standard queries, and performing routine data cleaning — you are in the direct path of AI automation. Medidata Rave AI and Veeva Vault CDMS already handle these tasks with human review. Your role shrinks to validating AI output rather than doing the work yourself, and fewer humans are needed for that validation. 2-4 year window.
If you deeply understand CDISC standards, can interpret complex protocol requirements, and serve as the bridge between clinical science and data management — you are safer than the Yellow label suggests. Regulatory submissions require humans who understand both the clinical context and the data standards. This person becomes the "clinical data quality lead" who configures AI tools, validates their output, and owns the regulatory sign-off.
The single biggest separator: whether your value comes from executing data tasks (cleaning, queries, edit checks) or from clinical and regulatory judgment (interpreting protocols, ensuring CDISC compliance, owning safety data integrity). The execution layer is automating. The judgment layer persists — but it's a smaller, more senior role.
What This Means
The role in 2028: The surviving clinical data analyst looks more like a clinical data quality specialist. Less time on manual query resolution and edit check programming — AI handles the volume work. More time configuring AI validation tools, auditing AI-generated SDTM mappings, and ensuring regulatory compliance across increasingly automated workflows. Headcount per trial drops 30-40%, but the remaining analysts are more senior, better paid, and focused on regulatory accountability.
Survival strategy:
- Deepen CDISC and regulatory expertise. Become the person who ensures AI-generated datasets meet FDA/EMA submission requirements. CDISC SDTM/ADaM certification, combined with understanding of 21 CFR Part 11 and EU CTR requirements, creates a regulatory moat that AI cannot cross without human sign-off.
- Learn to configure and validate AI tools in CDM platforms. Master the AI modules in Medidata Rave, Veeva Vault, or Oracle Clinical One. The analyst who configures AI edit checks and validates AI query generation is more valuable than the one who runs them manually.
- Move toward clinical data management or clinical informatics. The career path upward — into CDM leadership, clinical informatics, or regulatory data strategy — is more protected. Senior CDMs who own Data Management Plans and make judgment calls on data integrity score higher because they bear accountability AI cannot hold.
Where to look next. If you're considering a career shift, these Green Zone roles share transferable skills with clinical data analysis:
- Biostatistician (AIJRI 48.1) — CDISC knowledge, clinical trial expertise, and data quality skills transfer directly to statistical analysis design and regulatory submissions
- Data Protection Officer (AIJRI 50.7) — Regulatory compliance experience (GCP, HIPAA, FDA) and data governance skills map to privacy oversight in healthcare
- Clinical Informatics Specialist (AIJRI ~40+) — Clinical domain knowledge, EDC system expertise, and data standards experience provide a foundation for health IT systems design
Browse all scored roles at jobzonerisk.com to find the right fit for your skills and interests.
Timeline: 3-5 years for significant headcount compression per trial. Regulatory inertia slows adoption — FDA validation requirements for AI tools in clinical data management add 1-2 years versus unregulated industries. But the direction is clear: fewer analysts doing higher-value work with AI handling the volume.
